INTRODUCTION: Nonsurgical treatments, such as sclerotherapy have been attempted for head and neck lymphagiomas. Of the available sclerosing agents, picibanil has shown satisfactory short-term treatment results in many studies, but no study has presented long-term treatment results. Accordingly, in the present study, the authors retrospectively reviewed the long-term treatment results of picibanil sclerotherapy. MATERIALS AND METHODS: Fifty-five lymphangioma patients who underwent picibanil sclerotherapy were enrolled. Data about initial and long-term response, recurrence, and excision rate were collected. RESULTS: Initial response rates were 83.5 percent and long-term response rates were 76.3 percent. CONCLUSION: Initial and the long-term response rate were equally good for lymphangioma.
INTRODUCTION: Nonsurgical treatments, such as sclerotherapy have been attempted for head and neck lymphagiomas. Of the available sclerosing agents, picibanil has shown satisfactory short-term treatment results in many studies, but no study has presented long-term treatment results. Accordingly, in the present study, the authors retrospectively reviewed the long-term treatment results of picibanil sclerotherapy. MATERIALS AND METHODS: Fifty-five lymphangiomapatients who underwent picibanil sclerotherapy were enrolled. Data about initial and long-term response, recurrence, and excision rate were collected. RESULTS: Initial response rates were 83.5 percent and long-term response rates were 76.3 percent. CONCLUSION: Initial and the long-term response rate were equally good for lymphangioma.
Authors: Maliha Sadick; Walter A Wohlgemuth; Roland Huelse; Bettina Lange; Thomas Henzler; Stefan O Schoenberg; Haneen Sadick Journal: Eur J Radiol Open Date: 2017-05-14